Osteal Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4835 Lyndon B Johnson Fwy Ste 635, Dalla...Website
www.ostealtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Osteal Therapeutics
Osteal Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative musculoskeletal therapeutics aimed at treating orthopedic infections and their consequences. The company is dedicated to improving patient outcomes by providing targeted treatments that enhance quality of life and reduce healthcare costs associated with these infections. Their mission is to support orthopedic surgeons with effective tools to resolve infections quickly and reliably, ultimately preserving limbs and lives. Osteal Therapeutics serves patients suffering from orthopedic infections and the healthcare professionals who treat them.Explore more
Osteal Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Osteal Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Osteal Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Osteal Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Osteal Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Osteal Therapeutics launches new products
Click to see if Osteal Therapeutics had a recent Job posting/layoffs
Check if Osteal Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Osteal Therapeutics
Earning: See what the market has to say on Osteal Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Osteal Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Osteal Therapeutics
Compare insights from companies similar to Osteal Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Osteal Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Osteal Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Osteal Therapeutics.
Osteal Therapeutics financials insights
Gather financial insights about Osteal Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series C
$23M
2024
Series D
$50M
Osteal Therapeutics Tech Stack
A closer look at the technologies used by Osteal Therapeutics
Most Recent Scoops
Open Position
Event
Product Marketing, Events, Training, Sales, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Technology, HR Operations, Operations
Funding
Funding
Promotion
Executive Move
Osteal Therapeutics has announced that Trey Putnam has been promoted from Vice President, Regulatory Affairs & Quality Assurance to the role of Chief Operating Officer.
Funding
Osteal Therapeutics News & Media
Osteal Therapeutics Presents Positive Six-Month Results from the APEX Clinical Trial Program at the 34th Annual Musculoskeletal Infection Society Meeting
The six-month efficacy endpoint of overall success showed a statistically significant improvement over standard of care, two-stage exchange arthroplasty The six-month efficacy endpoint of overall success showed a statistically significant improvement over standard of care, two-stage exchange arthroplastyOsteal Therapeutics Closes $50M Series D Financing | Orthopedics This Week
Osteal Therapeutics completed an oversubscribed $50 million Series D preferred stock equity financing round.Osteal Therapeutics Closes $50M Series D Financing
DALLAS, June 05, 2024 (GLOBE NEWSWIRE) — Osteal Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new category of combination... Read More The post Osteal Therapeutics Closes $50M Series D Financing appeared first on citybiz.Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Osteal Therapeutics
Sign Up For FreeTo access detailed company insights
Osteal Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative musculoskeletal therapeutics aimed at treating orthopedic infections and their consequences. The company is dedicated to improving patient outcomes by providing targeted treatments that enhance quality of life and reduce healthcare costs associated with... Read More
